Differential Pharmacokinetics and Pharmacodynamics of Methylphenidate Enantiomers
- 1 June 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 28 (3), S54-S61
- https://doi.org/10.1097/jcp.0b013e3181733560
Abstract
D,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release. Although MPH has long been administered as a racemic mixture of the 2 enantiomers, d-MPH and l-MPH, converging lines of evidence drawn from investigations using in vitro systems, animal models, and humans indicate that it is predominantly, if not exclusively, d-MPH that mediates the pharmacological/therapeutic actions of MPH. In both rodent and primate animal models, the binding of radiolabeled d-MPH to dopamine transporter was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific. The behavioral effects of the enantiomers of MPH have been tested in several animal models, and results indicate these observed behavioral changes are likewise mediated by d-MPH, whereas l-MPH has little or no effect.The contribution of the l-isomer to the overall pharmacological profile of the racemate remains unclear, owing to several studies suggesting that l-MPH may not be merely an inert isomeric ballast. For example, behavioral studies conducted in rats demonstrate an attenuation of the effect of d-MPH in animals pretreated with l-MPH, suggesting that l-MPH may interfere with the action of the active enantiomer. The importance of MPH chirality to central nervous system MPH receptor targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific. Taken together, data from in vitro, animal, and human studies support the premise that the d-enantiomer of MPH mediates the neurophysiological actions of MPH and therefore likely mediates its clinical efficacy.Keywords
This publication has 51 references indexed in Scilit:
- Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the EvidencePediatrics, 2005
- Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1The Journal of pharmacology and experimental therapeutics, 2004
- A review of the pharmacotherapy of adults with Attention-Deficit/ Hyperactivity DisorderJournal of Attention Disorders, 2001
- Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteersEuropean Journal of Clinical Pharmacology, 1993
- Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in HumansPharmaceutical Research, 1993
- Enantioselective pharmacokinetics and pharmacodynamics of dl-thero-mcthylphenidate in children with attention deficit hyperactivity disorderClinical Pharmacology & Therapeutics, 1992
- Enantioselective gas chromatographic assay with electron-capture detection for dl-ritalinic acid in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Kinetic Analysis of Enantiomers of Threo-Methylphenidate and Its Metabolite in Two Healthy Subjects after Oral Administration as Determined by a Gas Chromatographic-Mass Spectrometric MethodJournal of Pharmaceutical Sciences, 1990
- Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the Administration of a Sustained-Release Formulation to Children with Attention Deficit-Hyperactivity DisorderJournal of Pharmaceutical Sciences, 1989
- Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1986